Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Classification of lymphomas].

Thierry Molina1, Jacques Diebold, Josée Audouin

  • 1Service central d'anatomie et de cytologie pathologiques Jacques Delarue L'Hôtel-Dieu, 75181 Paris. thierry.molina@htd.ap-hop-paris.fr

La Revue Du Praticien
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same author

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

medRxiv : the preprint server for health sciences·2026
Same author

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Machine learning to classify the focus score and Sjögren's disease using digitalised salivary gland biopsies: a retrospective cohort study.

The Lancet. Rheumatology·2025
Same author

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Blood advances·2025
Same author

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Leukemia·2024
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

The 2001 World Health Organization classification offers a new lymphoma and lymphoid leukaemia system. It details 40 entities based on morphology, immunophenotype, genetics, and clinical presentation, differentiating B-cell from T/NK cell lymphomas.

Area of Science:

  • Hematopathology
  • Hematology
  • Oncology

Context:

  • The 2001 World Health Organization (WHO) classification represents a significant advancement in understanding lymphoid malignancies.
  • This consensus-driven system integrates expertise from hematopathology, hematology, and oncology.
  • It addresses the complexity of lymphomas and lymphoid leukaemias, acknowledging shared features between tumor masses and leukaemic phases.

Purpose:

  • To establish a standardized, comprehensive classification of lymphomas and lymphoid leukaemias.
  • To delineate approximately 40 distinct entities based on integrated diagnostic criteria.
  • To differentiate between B-cell and T/NK (natural killer) cell lymphomas.

Summary:

  • The 2001 WHO classification describes around 40 lymphoma entities using morphology, immunophenotype, genetic, and clinical data.

Related Experiment Videos

  • It unifies lymphomas and lymphoid leukaemias, recognizing commonalities in tumorous and leukaemic presentations.
  • Key distinctions are made between B-cell and T/NK cell lymphomas, and traditional grading is omitted.

    • Impact:

    • Provides a unified framework for diagnosing and managing lymphomas and lymphoid leukaemias.
    • Facilitates clearer communication and research collaboration among hematologists and oncologists globally.
    • Establishes a foundation for future advancements in lymphoid malignancy classification and treatment.